prikaz prve stranice dokumenta Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
  Download
PDF 1.17 MB
Scientific paper - Original scientific paper
Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
Medicina, 60 (2024), 11; 1905. https://doi.org/10.3390/medicina60111905
Batinić, Josip; Dreta, Barbara; Rinčić, Goran; Mrdeža, Antonia; Jakobac, Karla Mišura; Krišto, Delfa Radić; Vujčić, Milan; Piršić, Mario; Jonjić, Željko; Periša, Vlatka; Sinčić Petričević, Jasminka; Coha, Božena; Holik, Hrvoje; Valković, Toni; Stanić, Marija; Krečak, Ivan; Stojanović, Ante; Sajfert, Domagoj; Bašić-Kinda, Sandra More authors...

Cite this document

Batinić, J., Dreta, B., Rinčić, G., Mrdeža, A., Jakobac, K. M., Krišto, D. R. ... Bašić Kinda, S. (2024). Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM). Medicina, 60. (11). doi: 10.3390/medicina60111905

Batinić, Josip, et al. "Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)." Medicina, vol. 60, no. 11, 2024. https://doi.org/10.3390/medicina60111905

Batinić, Josip, Barbara Dreta, Goran Rinčić, Antonia Mrdeža, Karla Mišura Jakobac, Delfa Radić Krišto, Milan Vujčić, et al. "Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)." Medicina 60, no. 11 (2024). https://doi.org/10.3390/medicina60111905

Batinić, J., et al. (2024) 'Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)', Medicina, 60(11). doi: 10.3390/medicina60111905

Batinić J, Dreta B, Rinčić G, Mrdeža A, Jakobac KM, Krišto DR, and sur.. Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM). Medicina [Internet]. 2024 November 20 [cited 2024 December 02];60(11). doi: 10.3390/medicina60111905

J. Batinić, et al., "Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)", Medicina, vol. 60, no. 11, November 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:534883. [Accessed: 02 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
AuthorJosip Batinić
AuthorBarbara Dreta
AuthorGoran Rinčić
AuthorAntonia Mrdeža
AuthorKarla Mišura Jakobac
AuthorDelfa Radić Krišto
AuthorMilan Vujčić
AuthorMario Piršić
AuthorŽeljko Jonjić
AuthorVlatka Periša
AuthorJasminka Sinčić Petričević
AuthorBožena Coha
AuthorHrvoje Holik
AuthorToni Valković
AuthorMarija Stanić
AuthorIvan Krečak
AuthorAnte Stojanović
AuthorDomagoj Sajfert
AuthorSandra Bašić-Kinda
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Background and Objectives: Ixazomib, used in combination with lenalidomide and dexamethasone (IRd), has shown efficacy in clinical trials for relapsed/refractory multiple myeloma (RRMM). Materials and Methods: This study evaluates the real-world effectiveness and safety of IRd in Croatian RRMM patients. A retrospective analysis was conducted on 164 RRMM patients treated with ixazomib at nine Croatian haematology centres from November 2016 to February 2023. Data on patient demographics, treatment regimens, and outcomes were collected and analysed using Kaplan–Meier survival curves and Cox proportional hazards models in R. The median age at ixazomib initiation was 66 years (range 40–91). Results: The overall response rate (ORR) was 65.8%, with 42% of patients achieving a very good partial response (VGPR) or better. The median progression-free survival (PFS) was 15.4 months, while median overall survival (OS) was 28.2 months. Hematologic toxicities included anaemia (53%), neutropenia (50%), and thrombocytopenia (45%). Infective complications, primarily COVID-19 and pneumonia, were reported in 38% of patients. The safety profile was consistent with previous studies, indicating manageable adverse events. Ixazomib-based therapy is effective and well tolerated in a real-world Croatian RRMM population. Conclusions: The findings align with clinical trial results, demonstrating the applicability of ixazomib in routine clinical practice. Further studies are needed to optimise treatment sequencing and improve patient outcomes.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleMedicina
Numberingvol. 60, no. 11, 1905
e-ISSN1648-9144
DOIhttps://doi.org/10.3390/medicina60111905
URN:NBNurn:nbn:hr:184:534883
Publication2024-11-20
Document URLhttps://www.mdpi.com/1648-9144/60/11/1905
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-11-27 13:12:18